Clearstead Advisors’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $213K | Sell |
1,260
-18
| -1% | -$3.11K | ﹤0.01% | 983 |
|
|
2025
Q4 | $233K | Sell |
1,278
-50
| -4% | -$6.98K | ﹤0.01% | 897 |
|
|
2025
Q3 | $161K | Buy |
1,328
+136
| +11% | +$15.3K | ﹤0.01% | 927 |
|
|
2025
Q2 | $124K | Buy |
1,192
+60
| +5% | +$6.35K | ﹤0.01% | 1002 |
|
|
2025
Q1 | $132K | Sell |
1,132
-250
| -18% | -$28.5K | ﹤0.01% | 924 |
|
|
2024
Q4 | $117K | Buy |
1,382
+50
| +4% | +$4.6K | ﹤0.01% | 983 |
|
|
2024
Q3 | $120K | Hold |
1,332
| – | – | ﹤0.01% | 984 |
|
|
2024
Q2 | $107K | Buy |
1,332
+32
| +2% | +$2.37K | ﹤0.01% | 983 |
|
|
2024
Q1 | $98.3K | Sell |
1,300
-50
| -4% | -$4.2K | ﹤0.01% | 613 |
|
|
2023
Q4 | $107K | Sell |
1,350
-1,350
| -50% | -$90.3K | 0.01% | 571 |
|
|
2023
Q3 | $189K | Buy |
2,700
+1,350
| +100% | +$101K | 0.01% | 576 |
|
|
2023
Q2 | $97K | Hold |
1,350
| – | – | 0.01% | 583 |
|
|
2023
Q1 | $83.3K | Hold |
1,350
| – | – | 0.01% | 544 |
|
|
2022
Q4 | $104K | Hold |
1,350
| – | – | 0.01% | 490 |
|
|
2022
Q3 | $60K | Hold |
1,350
| – | – | 0.01% | 576 |
|
|
2022
Q2 | $52K | Hold |
1,350
| – | – | ﹤0.01% | 609 |
|
|
2022
Q1 | $56K | Buy |
1,350
+300
| +29% | +$9.3K | ﹤0.01% | 655 |
|
|
2021
Q4 | $40K | Hold |
1,050
| – | – | ﹤0.01% | 692 |
|
|
2021
Q3 | $35K | Hold |
1,050
| – | – | ﹤0.01% | 667 |
|
|
2021
Q2 | $71K | Hold |
1,050
| – | – | 0.01% | 506 |
|
|
2021
Q1 | $59K | Buy |
1,050
+50
| +5% | +$3.52K | ﹤0.01% | 521 |
|
|
2020
Q4 | $81K | Hold |
1,000
| – | – | 0.01% | 449 |
|
|
2020
Q3 | $71K | Buy |
+1,000
| New | +$77.9K | 0.01% | 414 |
|
Other funds holding AXSM
VPM
VCM
DTC
